FDA removed black-box warnings from three additional estrogen patches.
Regulators did not convene an advisory committee prior to the decision.
Experts expressed concern regarding a lack of transparency and justification.
Officials stated the change helps address ongoing nationwide patch shortages.
Read the full story on NexVani Media